Glucose Biosensors Market Size - By Type (Continuous Glucose Monitoring, Self-monitoring Blood Glucose), By Technology (Electrochemical Biosensors, Optical Biosensors), By End-Use (Hospitals, Home Care, Diagnostic Centers & Clinics), Global Forecast, 2032

Glucose Biosensors Market Size - By Type (Continuous Glucose Monitoring, Self-monitoring Blood Glucose), By Technology (Electrochemical Biosensors, Optical Biosensors), By End-Use (Hospitals, Home Care, Diagnostic Centers & Clinics), Global Forecast, 2032-2032

Glucose Biosensors Market size is projected to grow at over 13% CAGR from 2023 to 2032, driven by the ongoing innovations in biosensor technology.

Technological advancements have led to the development of more accurate, compact, and user-friendly glucose biosensors to offer improved precision of glucose measurements and enhanced convenience and comfort for users. For instance, in June 2023, San Diego-based Dexcom revealed plans to bring a new glucose-sensing technology product to the U.S. market by 2024. Furthermore, the ongoing R&D efforts resulting in cost-effective biosensors, leading to higher adoption among healthcare providers and individuals with diabetes will augment the market outlook.

The overall glucose biosensors market is categorized based on type, technology, end-use, and region.

With respect to type, the market value from the continuous glucose monitoring (CGM) segment is poised to gain significant traction through 2032 owing to the increasing patient awareness levels regarding diabetes type 1 worldwide. In 2022, the International Diabetes Federation reported that 8.75 million individuals across the globe have type 1 diabetes. Furthermore, the rising advancements in CGM technology have led to more accurate, user-friendly, and cost-effective devices, adding to the market growth.

In terms of end-use, the glucose biosensors industry size from the hospitals segment generated substantial revenue in 2022 and is forecasted to expand at 13.8% CAGR from 2023-2032. The growth is due to the rising prevalence of people suffering from diabetes and its complications. According to study published in 2021, nearly 25% of patients suffering from diabetes type 1 and 30% with diabetes type 2 are admitted to hospitals every year. The demand for accurate, real-time glucose monitoring devices in hospital settings is also on the rise for enabling timely interventions and better glycemic control for ultimately improving patient outcomes.

Europe held sizable share of the global glucose biosensors market in 2022 and is poised to grow at notable CAGR from 2023-2032 attributed to the growing healthcare expenditure and rising technological advancements in glucose biosensors. Favorable reimbursement policies for glucose monitoring devices and the strong presence of prominent market players are also contributing to the market expansion. Additionally, the rising disposable incomes of consumers coupled with the increasing availability of advanced products is projected to boost the regional market growth. For instance, in September 2023, Medtronic announced that its simplified Simplera CGM received the CE mark approval, setting it up for its introduction in Europe.